Physician profile
Stuart Topkis
NPI 1134216179
$3,144.97
in general payments reported to CMS, 2019-2025
29 companies · $78.99 in 2025
The $78.99 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $878 · 2020: $458 · 2021: $670 · 2022: $276 · 2023: $371 · 2024: $414 · 2025: $78.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $863.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $405.82 | 2019-2024 | Xarelto |
| Pfizer INC. | $303.78 | 2019-2023 | |
| Lilly USA, LLC | $259.53 | 2019-2024 | Jardiance |
| Abbvie INC. | $230.26 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $215.42 | 2019-2024 | Farxiga, Airsupra |
| Novo Nordisk INC | $194.54 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $174.98 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $171.47 | 2022-2025 | |
| Abbott Laboratories | $166.08 | 2021-2024 | Freestyle Libre 3, Proclaim |
| Amgen INC. | $159.02 | 2019-2020 | |
| Amarin Pharma, INC. | $137.26 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $102.28 | 2021-2025 | |
| Allergan, INC. | $76.94 | 2019-2020 | |
| Inspire Medical Systems, INC. | $66.71 | 2024 | Inspire |
| Glaxosmithkline, LLC. | $59.19 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.40 | 2019-2023 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.44 | 2020-2023 | Stiolto Respimat, Spiriva Respimat |
| Scilex Pharmaceuticals INC. | $50.40 | 2019-2020 | |
| Axsome Therapeutics, INC. | $47.25 | 2023-2024 | Auvelity |
| Biohaven Pharmaceuticals, INC. | $44.12 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $41.39 | 2021 | |
| Horizon Therapeutics Plc | $23.15 | 2019 | |
| Adlon Therapeutics L.P. | $22.09 | 2020 | |
| Assertio Therapeutics, INC. | $17.17 | 2020 | |
| Novartis Pharmaceuticals Corporation | $14.89 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.91 | 2022 | |
| Astellas Pharma US INC | $13.34 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.18 | 2022 | |
| Clarus Therapeutics INC. | $10.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Topkis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.